The Apex Court, however, refused to pass interim order to restrain Ranbaxy from manufacturing drugs.

The PIL was filed last year against Ranbaxy for allegedly manufacturing and selling adulterated drugs. The petitioner cited the pharmaceutical giant's case in US where Ranbaxy USA admitted to selling substandard and adulterated drugs.

Ranbaxy had last month suspended all shipments of pharmaceutical ingredients produced at two local factories to review processes and controls.

The Toansa and Dewas plants are currently banned from shipping products to United States following quality concerns, so the suspension will hit supplies to other markets including Europe and India, sources said.

JPN

Latest News from India News Desk